CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas

Human Pathology

Volumn 41, Issue 2, 2010, Pages 271-280

  Luo, Robert F ^a   Zhao, Shuchun ^a   Tibshirani, Robert ^a   Myklebust, June H ^a   Sanyal, Mrinmoy ^a   Fernandez, Rosemary ^a   Gratzinger, Dita ^a   Marinelli, Robert J ^a   Lu, Zhi Shun ^a   Wong, Anna ^a   Levy, Ronald ^a   Levy, Shoshana ^a   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD81; Lymphoma; Tissue microarray

Indexed keywords

CD81 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; LMO2 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BIOPSY; CANCER RISK; FLOW CYTOMETRY; GERMINAL CENTER; HEMATOPOIETIC TISSUE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LARGE CELL LYMPHOMA; LYMPHOMA; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION;

ANTIGENS, CD; B-LYMPHOCYTES; CLUSTER ANALYSIS; FLOW CYTOMETRY; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHOMA, NON-HODGKIN; PALATINE TONSIL; T-LYMPHOCYTES; THYMUS GLAND; TISSUE ARRAY ANALYSIS;

EID: 73749084453     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.07.022     Document Type: Article

References (32)

1. Levy S., and Shoham T. The tetraspanin web modulates immune-signaling complexes. Nat Rev Immunol 5 (2005) 136-148
2. Shoham T., Rajapaksa R., Boucheix C., Tedder T.F., et al. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol 171 (2003) 4062-4072
3. Tedder T.F., Inaoki M., and Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6 (1997) 107-118
4. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
5. Weng W.K., and Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 44 (2003) 1113-1120
6. Rosa D., Saletti G., De Gregorio E., et al. Activation of naïve B lymphocytes via CD81, a pathogenic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 102 (2005) 18544-18549
7. Machida K., Cheng K.T., Pavio N., Sung V.M., and Lai M.M. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 79 (2005) 8079-8089
8. Serra A., Nuti S., Tavarini S., et al. Coligation of the hepatitis C virus receptor CD81 with CD28 primes naïve T lymphocytes to acquire type 2 effector function. J Immunol 181 (2008) 174-185
9. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
10. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
11. Monti S., Savage K.J., Kutok J.L., et al. Molecular profiling of diffuse large B cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105 (2005) 1851-1861
12. Rosenwald A., Wright G., Chan W.C., et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med 346 (2002) 1937-1947
13. Lossos I.S., Czerwinski D.K., Alizadeh A.A., et al. Prediction of survival in diffuse large-B cell lymphoma based on the expression of six genes. N Engl J Med 350 (2004) 1828-1837
14. Malumbres R., Chen J., Tibshirani R., et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111 (2008) 5509-5514
15. Natkunam Y., Zhao S., Mason D.Y., et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B cell lymphomas. Blood 109 (2007) 1636-1642
16. Natkunam Y., Farinha P., Hsi E.D., et al. LMO2 protein expression predicts survival in patients with diffuse large B cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 26 (2008) 447-454
17. Bair E., and Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2 (2004) E108
18. Hummel M., Bentink S., Berger H., et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354 (2006) 2419-2430
19. Lossos I.S., and Morgensztern D. Prognostic biomarkers in diffuse large B cell lymphoma. J Clin Oncol 24 (2006) 995-1007
20. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissue (2008), IARC Press, Lyon
21. Stokke T., Galteland E., Holte H., et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B cell non-Hodgkin's lymphoma. Int J Cancer 89 (2000) 313-324
22. Natkunam Y., Lossos I.S., Taidi B., et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation. Blood 105 (2005) 3979-3986
23. Mason D.Y., Micklem K., and Jones M. Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol 191 (2000) 452-461
24. Marinelli R.J., Montgomery K., Liu C.L., et al. The Stanford tissue microarray database. Nucleic Acids Res 36 (2008) D871-D877
25. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
26. Natkunam Y., Warnke R.A., Montgomery K., Falini B., and van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 14 (2001) 686-694
27. Mittelbrunn M., Yáñez-Mó M., Sancho D., Ursa A., and Sánchez-Madrid F. Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of the immune synapse in both T lymphocytes and APC. J Immunol 15 (2002) 6691-6695
28. Viswanatha D.S., and Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 60 (2007) 1378-1383
29. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 346 (2002) 235-242
30. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B cell lymphoma. J Clin Oncol 24 (2006) 3121-3127
31. Pfreundschuh M., Trümper L., Osterborg A., et al., MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol 7 (2006) 379-391
32. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol 23 (2005) 5027-5033